246 related articles for article (PubMed ID: 37527933)
21. Vascular K
Sung MW; Yang Z; Driggers CM; Patton BL; Mostofian B; Russo JD; Zuckerman DM; Shyng SL
Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34711681
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms of the inhibitory effects of propofol and thiamylal on sarcolemmal adenosine triphosphate-sensitive potassium channels.
Kawano T; Oshita S; Takahashi A; Tsutsumi Y; Tomiyama Y; Kitahata H; Kuroda Y; Nakaya Y
Anesthesiology; 2004 Feb; 100(2):338-46. PubMed ID: 14739809
[TBL] [Abstract][Full Text] [Related]
23. Molecular analysis of ATP-sensitive K(+) channel subunits expressed in mouse portal vein.
Yamamoto T; Takahara K; Inai T; Node K; Teramoto N
Vascul Pharmacol; 2015 Dec; 75():29-39. PubMed ID: 26163942
[TBL] [Abstract][Full Text] [Related]
24. Acute exposure of methylglyoxal leads to activation of KATP channels expressed in HEK293 cells.
Yang Y; Konduru AS; Cui N; Yu L; Trower TC; Shi W; Shi Y; Jiang C
Acta Pharmacol Sin; 2014 Jan; 35(1):58-64. PubMed ID: 24122011
[TBL] [Abstract][Full Text] [Related]
25. Molecular analysis of ATP-sensitive K⁺ channel subunits expressed in mouse vas deferens myocytes.
Iwasa K; Zhu HL; Shibata A; Maehara Y; Teramoto N
Br J Pharmacol; 2014 Jan; 171(1):145-57. PubMed ID: 24117345
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the ATP-sensitive potassium channels (KATP) expressed in guinea pig bladder smooth muscle cells.
Gopalakrishnan M; Whiteaker KL; Molinari EJ; Davis-Taber R; Scott VE; Shieh CC; Buckner SA; Milicic I; Cain JC; Postl S; Sullivan JP; Brioni JD
J Pharmacol Exp Ther; 1999 Apr; 289(1):551-8. PubMed ID: 10087049
[TBL] [Abstract][Full Text] [Related]
27. Pathophysiological Consequences of KATP Channel Overactivity and Pharmacological Response to Glibenclamide in Skeletal Muscle of a Murine Model of Cantù Syndrome.
Scala R; Maqoud F; Zizzo N; Mele A; Camerino GM; Zito FA; Ranieri G; McClenaghan C; Harter TM; Nichols CG; Tricarico D
Front Pharmacol; 2020; 11():604885. PubMed ID: 33329006
[TBL] [Abstract][Full Text] [Related]
28. K(ATP) channel gain-of-function leads to increased myocardial L-type Ca(2+) current and contractility in Cantu syndrome.
Levin MD; Singh GK; Zhang HX; Uchida K; Kozel BA; Stein PK; Kovacs A; Westenbroek RE; Catterall WA; Grange DK; Nichols CG
Proc Natl Acad Sci U S A; 2016 Jun; 113(24):6773-8. PubMed ID: 27247394
[TBL] [Abstract][Full Text] [Related]
29. SUR2 subtype (A and B)-dependent differential activation of the cloned ATP-sensitive K+ channels by pinacidil and nicorandil.
Shindo T; Yamada M; Isomoto S; Horio Y; Kurachi Y
Br J Pharmacol; 1998 Jul; 124(5):985-91. PubMed ID: 9692785
[TBL] [Abstract][Full Text] [Related]
30. Arginine vasopressin inhibits Kir6.1/SUR2B channel and constricts the mesenteric artery via V1a receptor and protein kinase C.
Shi W; Cui N; Shi Y; Zhang X; Yang Y; Jiang C
Am J Physiol Regul Integr Comp Physiol; 2007 Jul; 293(1):R191-9. PubMed ID: 17428891
[TBL] [Abstract][Full Text] [Related]
31. Regulation of myometrial contraction by ATP-sensitive potassium (KATP) channel via activation of SUR2B and Kir 6.2 in mouse.
Hong SH; Kyeong KS; Kim CH; Kim YC; Choi W; Yoo RY; Kim HS; Park YJ; Ji IW; Jeong EH; Kim HS; Xu WX; Lee SJ
J Vet Med Sci; 2016 Aug; 78(7):1153-9. PubMed ID: 27086859
[TBL] [Abstract][Full Text] [Related]
32. Coexpression with the inward rectifier K(+) channel Kir6.1 increases the affinity of the vascular sulfonylurea receptor SUR2B for glibenclamide.
Russ U; Hambrock A; Artunc F; Löffler-Walz C; Horio Y; Kurachi Y; Quast U
Mol Pharmacol; 1999 Nov; 56(5):955-61. PubMed ID: 10531400
[TBL] [Abstract][Full Text] [Related]
33. Decreased expression of aortic KIR6.1 and SUR2B in hypertension does not correlate with changes in the functional role of K(ATP) channels.
Blanco-Rivero J; Gamallo C; Aras-López R; Cobeño L; Cogolludo A; Pérez-Vizcaino F; Ferrer M; Balfagon G
Eur J Pharmacol; 2008 Jun; 587(1-3):204-8. PubMed ID: 18471810
[TBL] [Abstract][Full Text] [Related]
34. Discovery and Characterization of VU0542270, the First Selective Inhibitor of Vascular Kir6.1/SUR2B K
Li K; McClenahan SJ; Han C; Bungard JD; Rathnayake U; Boutaud O; Bauer JA; Days EL; Lindsley CW; Shelton EL; Denton JS
Mol Pharmacol; 2024 Feb; 105(3):202-212. PubMed ID: 38302135
[TBL] [Abstract][Full Text] [Related]
35. Differential response of K(ATP) channels containing SUR2A or SUR2B subunits to nucleotides and pinacidil.
Reimann F; Gribble FM; Ashcroft FM
Mol Pharmacol; 2000 Dec; 58(6):1318-25. PubMed ID: 11093769
[TBL] [Abstract][Full Text] [Related]
36. [Interventional effects of activating SUR2B/Kir6.1-type K
Zhao Y; Wang H
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2022 Nov; 38(6):604-610. PubMed ID: 37308403
[No Abstract] [Full Text] [Related]
37. Lymphedema as first clinical presentation of Cantu Syndrome: reversed phenotyping after identification of gain-of-function variant in ABCC9.
Gao J; McClenaghan C; Christiaans I; Alders M; van Duinen K; van Haelst MM; van Haaften G; Nichols CG
Eur J Hum Genet; 2023 Feb; 31(2):188-194. PubMed ID: 36336713
[TBL] [Abstract][Full Text] [Related]
38. The Mechanism of High-Output Cardiac Hypertrophy Arising From Potassium Channel Gain-of-Function in Cantú Syndrome.
McClenaghan C; Huang Y; Matkovich SJ; Kovacs A; Weinheimer CJ; Perez R; Broekelmann TJ; Harter TM; Lee JM; Remedi MS; Nichols CG
Function (Oxf); 2020; 1(1):zqaa004. PubMed ID: 32865539
[TBL] [Abstract][Full Text] [Related]
39. Complex consequences of Cantu syndrome SUR2 variant R1154Q in genetically modified mice.
Zhang H; Hanson A; de Almeida TS; Emfinger C; McClenaghan C; Harter T; Yan Z; Cooper PE; Brown GS; Arakel EC; Mecham RP; Kovacs A; Halabi CM; Schwappach B; Remedi MS; Nichols CG
JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33529173
[TBL] [Abstract][Full Text] [Related]
40. The Kir6.2-F333I mutation differentially modulates KATP channels composed of SUR1 or SUR2 subunits.
Tammaro P; Ashcroft F
J Physiol; 2007 Jun; 581(Pt 3):1259-69. PubMed ID: 17395632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
